HCV therapeutics (Nanjing Sanhome Pharmaceutical)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameHCV therapeutics (Nanjing Sanhome Pharmaceutical)
Drug Alias Namehepatitis C virus NS5A and/or NS4A inhibitors (Nanjing Sanhome Pharmaceutical)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitorsNonstructural protein 5A inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymeraseNonstructural protein 5A
Therapy Area/IndicationsHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesNanjing Sanhome Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNanjing Sanhome Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsHepatitis C

Other Information

ATC CodeN/A
Related LinksN/A